{"originalText": "，缘于入院前3月余因“直肠癌”于2016.08.25在我科行“腹腔镜上直肠根治性切除术+预防性回肠造瘘术”，术顺，恢复良好，术后病理（201630447），：（直肠），：肠隆起型中分化管状腺癌，侵及深肌层，未见明确侵犯脉管及神经组织，手术标本双切端及另送（下切端）、（上切端）均未见癌浸润；找到肠周淋巴结13个，及另送（肠系膜上动脉根部）淋巴结3个均未见癌转移。，免疫组化结果：肿瘤细胞示KI67（30%+），P53（30%+），CEA（+），CK7（-），CK20（+），CDX2（+）。因患者要求化疗，后于2016.10.24、2016.11.15予“奥沙利铂（乐沙定）200MGIVGTTD1+卡培他滨1000MGPOBIDD1-D14”方案化疗，辅以水化、保肝、止吐、增强免疫力等处理，未出现明显化疗副反应。此后今为第3次化疗再次就诊我院，门诊拟“直肠癌术后化疗”收入院。自下次出院以来精神、睡眠、饮食可，无腹痛、腹胀、发热，小便正常，造口排便正常，体重较前无明显变化。", "entities": [{"label_type": "疾病和诊断", "overlap": 0, "start_pos": 11, "end_pos": 14}, {"label_type": "手术", "overlap": 0, "start_pos": 31, "end_pos": 52}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 79, "end_pos": 96}, {"end_pos": 152, "label_type": "解剖部位", "overlap": 0, "start_pos": 147}, {"end_pos": 172, "label_type": "解剖部位", "overlap": 0, "start_pos": 159}, {"end_pos": 282, "label_type": "药物", "overlap": 0, "start_pos": 278}, {"end_pos": 286, "label_type": "药物", "overlap": 0, "start_pos": 283}, {"end_pos": 304, "label_type": "药物", "overlap": 0, "start_pos": 300}, {"end_pos": 334, "label_type": "解剖部位", "overlap": 0, "start_pos": 333}, {"label_type": "疾病和诊断", "overlap": 0, "start_pos": 378, "end_pos": 383}, {"end_pos": 409, "label_type": "解剖部位", "overlap": 0, "start_pos": 408}, {"end_pos": 412, "label_type": "解剖部位", "overlap": 0, "start_pos": 411}]}
